@article{3a75eaf9deb64d4aa0b01b7b184f425b,
title = "R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma",
keywords = "Anthracyclines/therapeutic use, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Cyclophosphamide/therapeutic use, Humans, Lymphoma, Large B-Cell, Diffuse/pathology, Prednisone/therapeutic use, Treatment Outcome, Vincristine/therapeutic use",
author = "Diana Al-Sarayfi and Meeuwes, \{Frederik O.\} and M{\"u}jde Durmaz and Issa, \{Djamila E.\} and Brouwer, \{Rolf E.\} and Aart Beeker and \{van Rhenen\}, Anna and Mutsaers, \{Pim G.N.J.\} and B{\"o}hmer, \{Lara H.\} and \{van der Poel\}, \{Marjolein W.M.\} and \{te Boome\}, Liane and \{van Meerten\}, Tom and Chamuleau, \{Martine E.D.\} and Zijlstra, \{Jos{\'e}e M.\} and Mirian Brink and Marcel Nijland",
year = "2022",
month = sep,
day = "2",
doi = "10.1038/s41408-022-00723-4",
language = "English",
volume = "12",
journal = "Blood cancer journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "9",
}